A 52-Week Study of the Efficacy of Rivastigmine in Patients with Mild to Moderately Severe Alzheimer’s Disease

Farlow, Martin, Anand, Ravi, Messina Jr, John, Hartman, Richard, Veach, Jeffrey·2000·European Neurology
DOI 10.1159/000008243

Cited by (333)

Items 101–200 of 333

  1. Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness
    Christina M. Wolfson, Mark Oremus, Vijay Kumar Shukla, Franco Momoli, Louise Demers, Anne Perrault, Yola Moride · 2002 · Clinical Therapeutics
  2. The Impact of Caregiver Executive Skills on Reports of Patient Functioning
    Kara Bottiggi Dassel, Frederick A. Schmitt · 2008 · The Gerontologist
  3. Cholinesterase inhibition: is there evidence for disease-modifying effects?
    Michael Fraser Shanks, Miia Kivipelto, Roger Alan Bullock, Roger M. Lane · 2009 · Current Medical Research and Opinion
  4. Current pharmacologic options for patients with Alzheimer's disease
    William E. Reichman · 2003 · Annals of General Hospital Psychiatry
  5. Guidelines for the treatment of Alzheimer’s disease from the Italian Association of Psychogeriatrics
    Caltagirone, Carlo, Bianchetti, Angelo, Luca, Monica Di, Mecocci, Patrizia, Padovani, Alessandro, Pirfo, Elvezio, Scapicchio, Pierluigi, Senin, Umberto, Trabucchi, Marco, Musicco, Massimo · 2005 · Drugs & Aging
  6. Progression from mild cognitive impairment to Alzheimer's disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment
    Steven H. Ferris, Agneta K. Nordberg, Hilkka S. Soininen, Taher Darreh‐Shori, Roger M. Lane · 2009 · Pharmacogenetics and Genomics
  7. DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease – a multicentre RCT
    Rob G. Jones, Bart Sheehan, Patrick P. J. Phillips, Edmund Juszczak, Jessica Adams, Ashley Baldwin, Clive G. Ballard, Sube Banerjee, Bob Barber, Peter Bentham et al. · 2009 · Trials
  8. Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients
    Ove Almkvist, Taher Darreh‐Shori, Elka D. Stefanova, René Spiegel, Agneta K. Nordberg · 2004 · European Journal of Neurology
  9. Cholinesterase Inhibitors in the Clinical Management of Alzheimer's Disease: Importance of Early and Persistent Treatment
    Benjamin Seltzer · 2006 · Journal of International Medical Research
  10. Pharmacologists and Alzheimer disease therapy: to boldly go where no scientist has gone before
    Cesare Mancuso, Raffaella Siciliano, Eugenio Barone, David Allan Butterfield, P Preziosi · 2011 · Expert Opinion on Investigational Drugs
  11. Safety and tolerability of transdermal and oral rivastigmine in Alzheimer’s disease and Parkinson’s disease dementia
    Darreh-Shori, Taher, Jelic, Vesna · 2010 · Expert Opinion on Drug Safety
  12. Adding Chinese herbal medicine to conventional therapy brings cognitive benefits to patients with Alzheimer’s disease: a retrospective analysis
    Jing Shi, Jingnian Ni, Tao Lu, Xuekai Zhang, Mingqing Wei, Ting Li, Weiwei Liu, Yongyan Wang, Yuanyuan Shi, Jinzhou Tian · 2017 · BMC Complementary and Alternative Medicine
  13. Drug Persistency of Two Cholinesterase Inhibitors
    Dong‐Churl Suh, Simu K. Thomas, Elmira Valiyeva, Stephen Arcona, Lien Vo · 2005 · Drugs & Aging
  14. Alzheimer’s Disease Animal Models: Elucidation of Biomarkers and Therapeutic Approaches for Cognitive Impairment
    T. NAKAI, Kiyofumi Yamada, Hiroyuki Mizoguchi · 2021 · International Journal of Molecular Sciences
  15. Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years
    Martin Rhys Farlow, Mary LuAnne Lilly, for the ENA713 B352 Study Group · 2005 · BMC Geriatrics
  16. Butyrylcholinesterase: impact on symptoms and progression of cognitive impairment
    Andrea Tasker, Elaine King Perry, Clive G. Ballard · 2005 · Expert Review of Neurotherapeutics
  17. The Neuroprotective Effects and Therapeutic Potential of the Chalcone Cardamonin for Alzheimer’s Disease
    Kimberly Barber, Patricia Mendonca, Karam F. A. Soliman · 2023 · Brain Sciences
  18. Rivastigmine effects on EEG spectra and three-dimensional LORETA functional imaging in Alzheimer’s disease
    Lorena R. R. Gianotti, Gabriella Künig, Pascal Luc Faber, Dietrich Lehmann, Roberto Domingo Pascual-Marqui, Kieko Kochi, Ursula Schreiter-Gasser · 2008 · Psychopharmacology
  19. What Constitutes Clinical Evidence for Neuroprotection in Alzheimer Disease
    Etsuro Mori, Mamoru Hashimoto, Kousik Krishnan, Pudugramam Murali Doraiswamy · 2006 · Alzheimer Disease & Associated Disorders
  20. Pharmacokinetics and Bioavailability of the Novel Rivastigmine Transdermal Patch Versus Rivastigmine Oral Solution in Healthy Elderly Subjects
    Gilbert Y. Lefèvre, Francoise Pommier, Greg Sedek, Mark J. Allison, Hsun‐Lun Aaron Huang, Beate Kiese, Yu‐Yun Ho, Silke Appel‐Dingemanse · 2008 · The Journal of Clinical Pharmacology
  21. Rivastigmine in Alzheimer Disease
    George Thomas Grossberg, Peter Irwin, Andrew Satlin, Peter G Mesenbrink, René Spiegel · 2004 · American Journal of Geriatric Psychiatry
  22. A population-based study of dosing and persistence with anti-dementia medications
    Linda Brewer, Kathleen Bennett, Cora McGreevy, David James Williams · 2013 · European Journal of Clinical Pharmacology
  23. Effect of Medications on Physical Function and Cognition in Nursing Home Residents with Dementia
    Sarah K. Dutcher, Gail B. Rattinger, PATRICIA W. LANGENBERG, Pankdeep T. Chhabra, Xinggang Liu, Paul B. Rosenberg, Jeannie‐Marie Leoutsakos, Linda Simoni‐Wastila, Loreen D. Walker, Christine S. Franey et al. · 2014 · Journal of the American Geriatrics Society
  24. Measuring cognition in advanced Alzheimer’s disease for clinical trials
    Frederick A. Schmitt, Dona E.C. Locke, John Wesson Ashford, ‌Barry Reisberg, Steven H. Ferris, Hans Jörg Möbius, Albrecht Stöffler · 2002 · Journal of neural transmission. Supplementum
  25. Power and sample size for clinical trials when efficacy is required in multiple endpoints: application to an Alzheimer's treatment trial
    Chengjie Xiong, Kai Fun Yu, Feng Gao, Yan Yan, Zhengjun Zhang · 2005 · Clinical Trials
  26. Treatment of dementia with neurotransmission modulation
    Sheila Anne Doggrell, Suzanne Evans · 2003 · Expert Opinion on Investigational Drugs
  27. Imaging treatment effects in Alzheimer's disease
    Annalena Venneri · 2007 · Magnetic Resonance Imaging
  28. Impact of Rivastigmine on Costs and on Time Spent in Caregiving for Families of Patients With Alzheimer’s Disease
    Deborah B. Marin, Karine Amaya, Roman Casciano, Katherine L. Puder, Juuan Casciano, Anthony J. Cuccia, Sobin Chang, Edward H. Snyder, Isaac Cheng · 2003 · International Psychogeriatrics
  29. Rivastigmine for Alzheimer's Disease
    Murray A. Raskind, Vinod Kumar, Lisa I. Malaty, John C. Messina, Richard D. Hartman, Ravi Anand · 2000 · The Primary Care Companion For CNS Disorders
  30. Review of rivastigmine and its clinical applications in Alzheimer’s disease and related disorders
    Abhilash K. Desai, George Thomas Grossberg · 2001 · Expert Opinion on Pharmacotherapy
  31. Cerebrospinal fluid brain‐derived proteins in the diagnosis of Alzheimer's disease and Creutzfeldt–Jakob disease
    A.J.E Green · 2002 · Neuropathology and Applied Neurobiology
  32. Treatment of Alzheimer’s disease in the long-term-care setting
    David A. Smith · 2009 · American Journal of Health-System Pharmacy
  33. Reduction of cortical amyloid β levels in guinea pig brain after systemic administration of physostigmine
    Thomas G. Beach, Yu‐Min Kuo, Claudia Schwab, Douglas G Walker, Alex E. Roher · 2001 · Neuroscience Letters
  34. Progress in Clinical Neurosciences: Treatment of Alzheimer’s Disease and Other Dementias - Review and Comparison of the Cholinesterase Inhibitors
    David B. Hogan, Christopher Patterson · 2002 · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
  35. Chronic Exposure of Rats to Cognition Enhancing Drugs Produces a Neuroplastic Response Identical to that Obtained by Complex Environment Rearing
    Keith J. Murphy, Andrew Foley, Alan W. O’Connell, Ciaran M. Regan · 2005 · Neuropsychopharmacology
  36. Treatments for Alzheimer Disease
    Darryl K. Potyk · 2005 · Southern Medical Journal
  37. Early Stage Glycosylation Biomarkers in Alzheimer’s Disease
    Patricia Regan, Paula L. McClean, Thomas J. Smyth, Margaret Doherty · 2019 · Medicines
  38. Is Long-Term Treatment of Alzheimer’s Disease with Cholinesterase Inhibitor Therapy Justified?
    Ben Seltzer · 2007 · Drugs & Aging
  39. Biological Markers in Alzheimer Disease
    Judith A. Neugroschl, Kenneth L. Davis · 2002 · American Journal of Geriatric Psychiatry
  40. Non-Pharmacological Interventions in Cognitively Impaired and Demented Patients - A Comparison with Cholinesterase Inhibitors
    Marijn W. Luijpen, Erik Scherder, Eus J.W. Van Someren, Dick Frans Swaab, Joseph A. Sergeant · 2003 · Reviews in the Neurosciences
  41. Dementia Update 2003
    John C. Morris · 2003 · Alzheimer Disease & Associated Disorders
  42. Treatment of Alzheimer's disease across the spectrum of severity
    Shailaja Shah, William E. Reichman · 2006 · Clinical Interventions in Aging
  43. Current status and new developments with galantamine in the treatment of Alzheimer’s disease
    Pierre N. Tariot · 2001 · Expert Opinion on Pharmacotherapy
  44. Understanding and Managing Behavioural Symptoms in Alzheimer's Disease and Related Dementias: Focus on Rivastigmine
    Philippe Henri Robert · 2002 · Current Medical Research and Opinion
  45. Rivastigmine: an update on therapeutic efficacy in Alzheimer's disease and other conditions
    C. Gabelli · 2003 · Current Medical Research and Opinion
  46. Exploring the Mechanisms and Therapeutic Approaches of Mitochondrial Dysfunction in Alzheimer’s Disease: An Educational Literature Review
    Mostafa Hossam El Din Moawad, Ibrahim Serag, Ibraheem M. Alkhawaldeh, Abdallah Abbas, Abdulrahman Sharaf, Sumaya Alsalah, Mohammed Ahmed Sadeq, Mahmoud Mohamed Mohamed Shalaby, Mahmoud Tarek Hefnawy, Mohamed Abouzid et al. · 2024 · Molecular Neurobiology
  47. EXACT: rivastigmine improves the high prevalence of attention deficits and mood and behaviour symptoms in Alzheimer's disease*
    Serge G. Gauthier, Angela G. Juby, Bonita Réhel, Robyn Schecter · 2007 · International Journal of Clinical Practice
  48. Update on Rivastigmine
    Martin Rhys Farlow · 2003 · The Neurologist
  49. Current and Emerging Therapies for Alzheimer’s Disease
    Haakon B. Nygaard · 2013 · Clinical Therapeutics
  50. Structural Model for the Binding Sites of Allosterically Potentiating Ligands on Nicotinic Acetylcholine Receptors
    Edgar Luttmann, Jürgen Ludwig, Anja Höffle‐Maas, Marek Samochocki, Alfred Maelicke, Gregor Fels · 2009 · ChemMedChem
  51. POTENTIAL LONG‐TERM EFFECTS OF RIVASTIGMINE ON DISEASE PROGRESSION MAY BE LINKED TO DRUG EFFECTS ON VASCULAR CHANGES IN ALZHEIMER BRAINS
    Timo Erkinjuntti, Ingmar Gr. Skoog, Roger M. Lane, C. Andrews · 2003 · International Journal of Clinical Practice
  52. A Review of Recent Advances in the Management of Alzheimer’s Disease
    Thangwaritorn Skylynn, Christopher Seungkyu Lee, Elena Metchikoff, Vidushi Razdan, Ghafary Suliman, Dominic Rivera, Alvaro Pinto, Sudhakar Pemminati · 2024 · Cureus
  53. Touchscreen-based location discrimination and paired associate learning tasks detect cognitive impairment at an early stage in an App knock-in mouse model of Alzheimer’s disease
    Ali Bin Saifullah, Okiru Komine, Yutao Dong, Kazuya Fukumoto, Akira Sobue, Fumito Endo, Takashi Saito, Takaomi C. Saido, Koji Yamanaka, Hiroyuki Mizoguchi · 2020 · Molecular Brain
  54. The role of basket trials in drug development for neurodegenerative disorders
    Jeffrey L. Cummings, Arturo Montes, Sana Kamboj, Jorge Ramón Fonseca Cacho · 2022 · Alzheimer s Research & Therapy
  55. Drug therapy in Alzheimer disease: an update for the oral health care provider
    Lena N. Turner, Ramesh Balasubramaniam, Elliot V. Hersh, Eric T. Stoopler · 2008 · Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology
  56. Alzheimer's Disease:Progress in the Development of Anti-amyloid Disease-Modifying Therapies
    Daniel D. Christensen · 2007 · CNS Spectrums
  57. Rivastigmine in Alzheimer's disease: Cognitive function and quality of life.
    Roberta Annicchiarico, Alessia Federici, Carla Pettenati, Carlo Caltagirone · 2007 · PubMed Central
  58. Tracking the decline in cerebral glucose metabolism in persons and laboratory animals at genetic risk for Alzheimer's disease
    Eric M. Reiman, Richard J. Caselli, Gene E. Alexander, Kewei Chen · 2001 · Clinical Neuroscience Research
  59. Glycoproteins as diagnostic and prognostic biomarkers for neurodegenerative diseases: A glycoproteomic approach
    Mingming Xu, Maotian Zhou, Shuwei Li, Xue‐chu Zhen, Shuang Yang · 2021 · Journal of Neuroscience Research
  60. Steady-State Pharmacokinetics of Rivastigmine in Patients with Mild to Moderate Alzheimer’s Disease Not Affected by Co-Administration of Memantine
    Joshua R. Shua‐Haim, Juanita M. Smith, Franck Picard, Greg Sedek, Sandeep N. Athalye, Francoise Pommier, Gilbert Y. Lefèvre · 2008 · Clinical Drug Investigation
  61. Results of a multi-level therapeutic approach for Alzheimer’s disease subjects in the “real world” (CRONOS project): a 36-week follow-up study
    Giuseppe Bellelli, Elena Lucchi, Nadia Minicuci, Luca Rozzini, Angelo Bianchetti, Alessandro Padovani, Marco Trabucchi · 2005 · Aging Clinical and Experimental Research
  62. Clinically tested drugs for Alzheimer?s disease
    Edith G. McGeer, Patrick L. McGeer · 2003 · Expert Opinion on Investigational Drugs
  63. Rivastigmine augmentation in the management of chronic schizophrenia with comorbid dementia: an open-label study investigating effects on cognition, behaviour and activities of daily living
    Erika Mendelsohn, Michal Rosenthal, Yosef Bohiri, Edith A. Werber, Moshe Kotler, Rael D. Strous · 2004 · International Clinical Psychopharmacology
  64. Effects of cholinesterase inhibitors appear greater in patients on established antihypertensive therapy
    Luca Rozzini, Barbara Vicini Chilovi, Giuseppe Bellelli, Erik Bertoletti, Marco Trabucchi, Alessandro Padovani · 2005 · International Journal of Geriatric Psychiatry
  65. Brain oscillatory patterns in mild cognitive impairment due to Alzheimer’s and Parkinson’s disease: An exploratory high-density EEG study
    Paola Polverino, Miloš Ajčević, Mauro Catalan, Giulia Mazzon, Claudio Bertolotti, Paolo Manganotti · 2022 · Clinical Neurophysiology
  66. Relationship Between the Efficacy of Rivastigmine and Apolipoprotein E (ε4) in Patients With Mild to Moderately Severe Alzheimer Disease
    Rafael Blesa, Miquel Aguilar, Jordi Peña‐Casanova, Merçé Boada, Sergi Martínez‐Ramírez, Jordi Alom, Carlos Hernández de la Hoz, Jerónimo Sancho, Óscar Fernández, Eulogio Gil-Neciga et al. · 2006 · Alzheimer Disease & Associated Disorders
  67. Mild cognitive impairment in Parkinson's disease: the challenge and the promise
    Hubert H. Fernandez, Gregory P. Crucian, Michael S. Okun, Catherine C. Price, Dawn Bowers · 2005 · Neuropsychiatric Disease and Treatment
  68. Beyond symptomatic therapy: a re-examination of acetylcholinesterase inhibitors in Alzheimer’s disease
    Norman R. Relkin · 2007 · Expert Review of Neurotherapeutics
  69. THE CLINICAL BENEFITS OF RIVASTIGMINE MAY REFLECT ITS DUAL INHIBITORY MODE OF ACTION: AN HYPOTHESIS
    R. Morris Bullock · 2002 · International Journal of Clinical Practice
  70. Pharmacotherapy for Alzheimer's Disease: 2002
    David S. Knopman · 2003 · Clinical Neuropharmacology
  71. Pharmacologic Treatment Expectations in the Management of Dementia with Lewy Bodies
    Daniel Kaufer · 2003 · Dementia and Geriatric Cognitive Disorders
  72. Drug Development in Alzheimer’s Disease: The Contribution of PET and SPECT
    Lieven Declercq, Rik R. Vandenberghe, Koen Van Laere, Alfons Verbruggen, Guy M Bormans · 2016 · Frontiers in Pharmacology
  73. Once-daily transdermal rivastigmine in the treatment of Alzheimer’s disease
    Richard C. Dodel · 2008 · Drug Design Development and Therapy
  74. Long-Term Cholinesterase Inhibitor Therapy for Alzheimer's Disease
    David Geldmacher · 2003 · The Primary Care Companion For CNS Disorders
  75. Rivastigmine in outpatient services: experience of 114 neurologists in Austria
    Reinhold Schmidt, Anita Lechner, Katja Petrovic · 2002 · International Clinical Psychopharmacology
  76. The Cost-Benefit of Cholinesterase Inhibitors in Mild to Moderate Dementia
    Grace Hui‐Min Wu, Krista L. Lanctôt, Nathan Herrmann, Shehnaz Moosa, PAUL I. OH · 2003 · CNS Drugs
  77. Cholinergic Modification of Neurogenesis and Gliosis Improves the Memory of AβPPswe/PSEN1dE9 Alzheimer’s Disease Model Mice Fed a High-Fat Diet
    Takeshi Matsuda, Tatsuhiro Hisatsune · 2016 · Journal of Alzheimer s Disease
  78. Impact of Study Design and Patient Population on Outcomes From Cholinesterase Inhibitor Trials
    Ravi Anand, Richard D. Hartman, Hyesung Sohn, Jacquiline Danyluk, Stephen M. Graham · 2003 · American Journal of Geriatric Psychiatry
  79. Potential Mechanisms of Tunneling Nanotube Formation and Their Role in Pathology Spread in Alzheimer’s Disease and Other Proteinopathies
    Szymon Kotarba, Marta Kozłowska, Małgorzata Scios, Kamil Saramowicz, Julia Barczuk, Zuzanna Granek, Natalia Siwecka, Wojciech Wiese, Michał Golberg, Grzegorz Galita et al. · 2024 · International Journal of Molecular Sciences
  80. A strategy to identify a ketoreductase that preferentially synthesizes pharmaceutically relevant (S)-alcohols using whole-cell biotransformation
    Saiful F. Haq, Anirudh P. Shanbhag, Subbulakshmi Karthikeyan, Imran Hassan, Kannan Thanukrishnan, Abhishek Ashok, Sunilkumar Sukumaran, Subramanian Ramaswamy, Nagakumar Bharatham, Santanu Datta et al. · 2018 · Microbial Cell Factories
  81. Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: A case-control study
    Shaoli Lu, Jerrold W. Hill, Howard M Fillit · 2005 · The American Journal of Geriatric Pharmacotherapy
  82. Targets, trials and tribulations in Alzheimer therapeutics
    Ruchita Gharat, Gargi Dixit, Mihir Khambete, Arati Prabhu · 2023 · European Journal of Pharmacology
  83. Patient Adherence to Transdermal Rivastigmine After Switching From Oral Donepezil
    Haijun Tian, Safiya Abouzaid, Wei Chen, Kristijan H. Kahler, Edward Kim · 2012 · Alzheimer Disease & Associated Disorders
  84. Dose-dependent Effects of Ladostigil on Microglial Activation and Cognition in Aged Rats
    Marta Weinstock, Corina Bejar, Donna Schorer-Apelbaum, Rony Panarsky, Lisandro Luques, Shai Shoham · 2013 · Journal of Neuroimmune Pharmacology
  85. We should not distinguish between symptomatic and disease‐modifying treatments in Alzheimer's disease drug development
    Rachelle Smith Doody · 2007 · Alzheimer s & Dementia
  86. Rational choice of cholinesterase inhibitor for the treatment of Alzheimer's disease in Canada: a comparative economic analysis
    J. Jaime, Denis Getsios, Kristen Migliaccio–Walle, Jack Ishak, Wissam El-Hadi, HEAD Study Group · 2003 · BMC Geriatrics
  87. Mitochondrial optic neuropathy: In vivo model of neurodegeneration and neuroprotective strategies
    Rojas · 2010 · Eye and Brain
  88. Drug therapy of dementia in elderly patients. A review
    Carsten Emil Olsen, Henrik Day Poulsen, Henrik Lublin · 2005 · Nordic Journal of Psychiatry
  89. Effect of acupuncture on patients with mild cognitive impairment assessed using functional near-infrared spectroscopy on week 12 (close-out): a pilot study protocol
    Eun-sun Jung, Jun-Hwan Lee, Kim Hyun-Tae, Sangsoo Park, Jieun Kim, Ji-yoon Cha, In-Chan Seol, Young-Eun Choi, Ho-ryong Yoo · 2018 · Integrative Medicine Research
  90. Concentrations of Rivastigmine and NAP 226-90 and the Cognitive Response in Taiwanese Alzheimer's Disease Patients
    Mei‐Chuan Chou, Chun‐Hung Chen, Ching‐Kuan Liu, Su‐Hwei Chen, Shyh-Jong Wu, Yuan‐Han Yang · 2012 · Journal of Alzheimer s Disease
  91. Cholinergic and glutamatergic drugs in Alzheimer’s disease therapy
    Nicholas A Clarke, Paul T. Francis · 2005 · Expert Review of Neurotherapeutics
  92. Safety/Tolerability and Efficacy of Rivastigmine in Taiwanese Patients with Alzheimerʼs Disease
    Pai‐Yi Chiu, Dao-En Dai, Hai-Pei Hsu, Chao Lee, Juei‐Jueng Lin, Hung‐Chou Kuo, Ying‐Chih Huang, Yung-Chang Liu, Ching‐Piao Tsai · 2009 · Clinical Drug Investigation
  93. Lower Barthel Index Scores Predict Less Prescription of Pharmacological Therapy in Elderly Patients with Alzheimer Disease
    Francesç Formiga, Isabel Fort, María José Robles, Daniel Rodríguez, Pedro Regalado · 2010 · Dementia and Geriatric Cognitive Disorders
  94. Effects of Renal Impairment on Steady-State Plasma Concentrations of Rivastigmine: A Population Pharmacokinetic Analysis of Capsule and Patch Formulations in Patients with Alzheimer’s Disease
    Gilbert Y. Lefèvre, Francesca Callegari, Sandro Gsteiger, Yuan Xiong · 2016 · Drugs & Aging
  95. Current issues in dementia pharmacotherapy.
    Lori A. Daiello · 2007 · PubMed
  96. What We Can Learn From Open-Label Extensions of Randomized Clinical Trials
    Jeffrey L. Cummings · 2006 · Archives of Neurology
  97. Mild Cognitive Impairment
    2006 · Wiley eBooks
  98. Current therapies for neurological disorders and their limitations
    Samaneh Rezaei, Korosh Morshedi, Rana Shafabakhsh, Maryam Mahjoubin‐Tehran · 2023 · Elsevier eBooks
  99. Mild Alzheimer's disease: A «Position Paper»
    Julien Delrieu, T. Voisin, Sandrine Andrieu, Serge Belliard, Joël Belmin, F. Blanchard, Mathieu Pierre Ceccaldi, Jean‐François Dartigues, Bénédicte Defontaines, Stéphane Lehéricy et al. · 2009 · The journal of nutrition health & aging
  100. Modeling the Cost-Effectiveness of Galantamine for Mild to Moderately Severe Alzheimer's Disease in Korea
    Guk‐Hee Suh · 2009 · Value in Health